| Literature DB >> 35409711 |
Terri-Ann Berry1, Elena Belluso2, Ruggero Vigliaturo2, Reto Gieré3, Edward A Emmett4, Joseph R Testa5, Gregor Steinhorn1, Shannon L Wallis1.
Abstract
There are six elongate mineral particles (EMPs) corresponding to specific dimensional and morphological criteria, known as asbestos. Responsible for health issues including asbestosis, and malignant mesothelioma, asbestos has been well researched. Despite this, significant exposure continues to occur throughout the world, potentially affecting 125 million people in the workplace and causing thousands of deaths annually from exposure in homes. However, there are other EMPS, such as fibrous/asbestiform erionite, that are classified as carcinogens and have been linked to cancers in areas where it has been incorporated into local building materials or released into the environment through earthmoving activities. Erionite is a more potent carcinogen than asbestos but as it is seldom used for commercial purposes, exposure pathways have been less well studied. Despite the apparent similarities between asbestos and fibrous erionite, their health risks and exposure pathways are quite different. This article examines the hazards presented by EMPs with a particular focus on fibrous erionite. It includes a discussion of the global locations of erionite and similar hazardous minerals, a comparison of the multiple exposure pathways for asbestos and fibrous erionite, a brief discussion of the confusing nomenclature associated with EMPs, and considerations of increasing global mesothelioma cases.Entities:
Keywords: asbestiform; asbestos fibres; erionite; exposure; malignant mesothelioma
Mesh:
Substances:
Year: 2022 PMID: 35409711 PMCID: PMC8998304 DOI: 10.3390/ijerph19074031
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Most common identified locations of zeolites and specific occurrences of erionite and offretite (without distinction between habits). Key: purple = zeolites (general); yellow = erionite (only); orange = offretite (only); red = erionite and offretite. References: Zeolite Mining–[31,32,33]. Erionite deposits–[34,35,36,37,38,39,40,41,42,43,44] and mentioned in [45]. Offretite deposits–[36,46].
Figure 2The four waves of asbestos exposure (figure based on Landrigan, 1991 [55]) and reproduced from Wallis et al., 2020 [54]).
Figure 3A summary of potential exposure pathways for asbestos exposure globally.
Summary of observed erionite exposure pathways and their link to evidence of MM (form and habit identified where possible).
| Location | Erionite Form/Species | Evidence of MM? | Main Exposure Pathways Highlighted |
|---|---|---|---|
| Rome, Oregon, USA | Fibrous, Erionite-K, | Test organisms (rats) only | Low population density, no exposure described [ |
| Zacatecas and Jalisco, Mexico | Not specified | Yes, human fatalities. Erionite confirmed in lung tissue of one MM case [ | Adobe bricks and terraces [ |
| Karlik, Cappadocia, Turkey | Fibrous, Erionite-K [ | Yes, human fatalities; low rate compared to neighbouring Karain [ | General low concentration; environmental exposure suggested responsible for the relatively low incidence rate of MM in Karlik [ |
| Karain, Cappadocia, Turkey | Fibrous, Erionite-K [ | Yes, human fatalities at extremely high rate [ | Living in houses built of materials containing erionite nodules [ |
| East Gate, Nevada, USA | Not specified | Not specified | Not specified |
| Dunn County, North Dakota, USA | Not specified | No | Gravel used as building materials, e.g., non-paved roads [ |
| Wyoming, South Dakota and Montana, USA | Fibrous, form not specified | No | Campground maintenance, universal terrain vehicle use, tree surgery, digging [ |
| Northern Italy, | Fibrous and asbestiform, | Elevated MM rates in the general region, but no detailed epidemiological study yet [ | Mining, quarrying and construction materials [ |
| Kandovan, Iran | Fibrous, form not specified | No | Construction and inhabitation of cave dwellings and agricultural use suspected [ |
| New Caledonia | Not specified | Not specified | Not specified |
| New Zealand | Not specified | Test organisms (rats) | Not specified [ |
Figure 4A summary of potential exposure pathways for erionite and other EMPs.
Demographics of MM cases worldwide.
| Country | No. MM Deaths per Year | Ave. Age at Diagnosis | Percentage of Population | No. of MM Cases | |
|---|---|---|---|---|---|
| New Zealand | 100–170 ^ | 50–60 * | 23.4–39.8 (2008) | 1.8–33 | 1971–1996 |
| USA | 3000 | 65–74 | 7.6 (2011) | 3200 +,** | 2003–2008 |
| Australia | 757 | 70–79 | 31.0 (2016) | 135–631 | 1982–2017 * |
| UK | 2500 | 75–79 * | 37.4 (2017) | 1164–2526 | 1982–2015 * |
| Canada | 515 | 60 | 15.1 (2010) | 153–344 | 1984–2003 |
| China | 1659 | N/A # | 1.2 (2013) | 2041 | 2013 |
| Brazil | 142 | N/A | 0.7 (2010) | N/A | 2008–2014 |
| Germany | 1480 | 74–75 | 18.0 (2016) | 1340 | 2016 |
| Netherlands | 481–1000 | N/A # | 29.0–60.2 (2010) | 2587 | 2008–2012 |
| World | 47,000 | - | 6.7 (2011) | 3718–9993 ** | 1994–2008 |
Key: ^ uncertainty whether this number includes other asbestos-related cancers; * men only; ** numbers based on mean for timeframe, # average age of diagnosis not available within data source(s). Note: The number of MM cases indicates the increase observed over the timeframe stated, except for the USA, for which there were minimal increases observed over the last several decades. References: [89,92,93,94,98,99,100,101,102,103,104,105].